Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate

Cellectis has filed an IND for US testing of its TALEN-edited CAR-T immune-oncology therapy UCART123. Servier has already begun clinical testing with Cellectis' lead program, UCART19, in Europe. The product is licensed to Pfizer in the US.